Opportunity Radar

← Back to search

Grant

Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)

View on Grants.gov ↗ Sign in to save

Type
Grant
Notice type
G
Agency
National Institutes of Health
Sub-agency
HHS-NIH11
Solicitation #
PAR-25-145
Posted
Nov 6, 2024
Response due
Jan 7, 2028
Archive date
Feb 12, 2028
CFDA / Assistance listing
93.393
Contact
grantsinfo@nih.gov
Source
Grants.gov

Description

The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.

Similar open opportunities